Apogee Therapeutics Inc
APGEHealthcare|Biotechnology|USA
$133.65
+0.08 (+0.06%)
Tangible Book
$16.77
Upcoming Data Readouts (4)
Sep 2026
Est. completion
P1Asthma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901n=31
Nov 2026
Est. completion
Dec 2026
Est. completion
P1Atopic Dermatitis
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
NCT07027527n=86
Dec 2029
Est. completion
P2Atopic Dermatitis
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT07003425n=350